herenciageneticayenfermedad: Prostate Cancer - Nov 15, 2018 Edition :: Medical News

jueves, 15 de noviembre de 2018

	November 15, 2018
	Prostate Cancer
	The latest prostate cancer news from News Medical

Patient Outcomes of Prostate Cancer with Whole Slide Imaging

An interview with Dr. Anil Parwani, discusses how whole slide imaging of prostate cancer sections is helping to inform pathologists and improve patient outcomes.

			Radiotherapy can prolong survival in prostate cancer A new major study from London has shown that radiotherapy can extend survival among patients with prostate cancer. The study shows that larger number of patients given standard therapy along with radiation therapy survived three years after the initiation of the study despite having a local spread of their cancer.

			Study defines biomarker in response to treatment of castration-resistant prostate cancer The most aggressive type of prostate cancer, castration-resistant prostate cancer, can be treated with two different therapies: taxanes or hormone treatment. Until this day there are no comparative studies between the two and the decision on which treatment to use is done empirically and based on the patient's preferences.

	Men with early prostate cancer choose lower survival odds to improve quality of life Men who have been newly diagnosed with prostate cancer say they would trade some improvement in their odds of survival for improvements in side effects and quality of life, according to research presented at the 2018 NCRI Cancer Conference.

	Study uses gold nanoparticles to remove prostate cancer cells A small clinical trial using gold nanoparticles that act as tumor-seeking missiles on a mission to remove prostate cancer has begun at The University of Texas Health Science Center at Houston (UTHealth). It is the first trial of its kind in the world.

	New type of molecule shows early promise against treatment-resistant prostate cancer A new type of molecule blocks the action of genes that drive the growth of therapy-resistant prostate cancer, a new study finds.

	Newly developed synthetic DNA molecule may one day be used as 'vaccine' for prostate cancer Researchers from City of Hope, a world-renowned comprehensive cancer center and independent biomedical research institution, have developed a synthetic DNA molecule that is programmed to jump-start the immune system to eradicate genetically distinct types of prostate cancer.